IPP Bureau
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
By IPP Bureau - December 23, 2025
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
By IPP Bureau - December 23, 2025
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial
By IPP Bureau - December 23, 2025
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar
By IPP Bureau - December 23, 2025
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries
By IPP Bureau - December 23, 2025
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Cupid reduces promoter pledged stake to 20%
By IPP Bureau - December 23, 2025
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
TAKE Solutions plans AI-driven healthcare platform
By IPP Bureau - December 23, 2025
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
Zydus Partners with Bioeq for US commercialisation rights for Nufymco
By IPP Bureau - December 23, 2025
NUFYMCO BLA has been approved by the USFDA
CARE Hospitals hosts insurance summit to strengthen trust in healthcare
By IPP Bureau - December 22, 2025
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
Care ADHD opens its first Global Capability Centre in India
By IPP Bureau - December 22, 2025
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
By IPP Bureau - December 22, 2025
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Ipsen’s FALKON trial falls short in rare FOP study, offers key insights
By IPP Bureau - December 22, 2025
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Xeureka & UBE launch joint cancer drug discovery program
By IPP Bureau - December 22, 2025
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Sai Life Sciences unveils 2024–25 sustainability report
By IPP Bureau - December 22, 2025
The company also reported significant progress toward its internally defined Sustainable Development Goals
MARAbio launches first blood test to detect maternal autoantibody-linked autism
By IPP Bureau - December 22, 2025
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
